RayKnowChina Research Map
Shortlist

RecruitingLung cancerPhase 2

Registered title, quoted from ClinicalTrials.gov

Toripalimab Combined With Cryoablation for First-line Oligo-progression in Driver-negative Advanced NSCLC

An open trial on lung cancer, registered on ClinicalTrials.gov. Led by Shanghai Chest Hospital; 2 other hospitals on this site are listed as study sites.

Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 3

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Lead sponsorShanghai Chest Hospital上海市胸科医院ShanghaiHospital page
  2. Study siteShanghai Ninth People's Hospital上海交通大学医学院附属第九人民医院ShanghaiHospital page
  3. Study siteZhongshan Hospital, Fudan University复旦大学附属中山医院ShanghaiHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT06127303, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 6

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (6 points)Hide the checklist
  1. 18 years to 75 years; sex: all

    Registered eligibility fields

  2. histologically or cytologically confirmed advanced metastatic (stage IV) non-small cell lung cancer;

    Inclusion criterion 2

  3. Patients with negative driver genes who develop oligoprogression after receiving standard first-line therapy. The oligoprogression is defined as: 1-5 metastatic lesions, and no more than 3 organs;

    Inclusion criterion 3

    International normalised ratio (INR) ≤1.5 and partial thromboplastin time (PTT or aPTT) ≤1.5 x ULN within 7 days prior to study treatment;

    Inclusion criterion 8

    Spinal cord compression for which operation and/or radical radiotherapy has not been given, or no clinical evidence of stable disease for ≥4 weeks prior to enrollment after treatment for previously diagnosed spinal cord compression;

    Exclusion criterion 5

  4. Age 18-75 years old; ECOG PS: 0-1; The expected survival is more than 3 months;

    Inclusion criterion 4

  5. cytologically or histologically confirmed combination with small cell lung cancer component or sarcomatoid element;

    Exclusion criterion 1

    Patients has HIV-positive;

    Exclusion criterion 15

  6. The man patients who must agree to take contraceptive methods during the research and within another 6 months after it.

    Inclusion criterion 10

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: stage or severity, as the trial defines it; blood tests: counts, liver and kidney function; scans and measurable lesions.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT06127303, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

  • Voluntary participation and written informed consent;
  • histologically or cytologically confirmed advanced metastatic (stage IV) non-small cell lung cancer;
  • Patients with negative driver genes who develop oligoprogression after receiving standard first-line therapy. The oligoprogression is defined as: 1-5 metastatic lesions, and no more than 3 organs;
  • Age 18-75 years old; ECOG PS: 0-1; The expected survival is more than 3 months;
  • At least one measurable lesion;
  • Patients were willing to provide adequate blood and tissue samples;
  • Patients had adequate hematologic, renal, and liver function;
  • International normalised ratio (INR) ≤1.5 and partial thromboplastin time (PTT or aPTT) ≤1.5 x ULN within 7 days prior to study treatment;
  • The woman patients of childbearing age who must agree to take contraceptive methods during the research;
  • The man patients who must agree to take contraceptive methods during the research and within another 6 months after it.

Exclusion Criteria:

  • cytologically or histologically confirmed combination with small cell lung cancer component or sarcomatoid element;
  • Previously received targeted therapy for advanced NSCLC (including osimertinib, erlotinib, crizotinib, etc);
  • Had undergone major surgical operations or had not fully recovered from previous operations within 3 weeks before enrollment;
  • Known active nervous system (CNS) metastases and/or carcinomatous meningitis;
  • Spinal cord compression for which operation and/or radical radiotherapy has not been given, or no clinical evidence of stable disease for ≥4 weeks prior to enrollment after treatment for previously diagnosed spinal cord compression;
  • Uncontrolled pleural effusion, pericardial effusion, or ascites requiring repeated drainage; patients with stable symptoms after drainage can be enrolled;
  • History of idiopathic pulmonary fibrosis, organized pneumonia (e.g., obliterating bronchiolitis), drug induced pneumonia, idiopathic pneumonia or evidence of active pneumonia during chest CT scanning for screening;
  • Clinically uncontrolled active infection, including but not limited to acute pneumonia;
  • Uncontrollable major epileptic seizure or superior vena cava syndrome;
  • Previous or current co-occurrence of other malignancies (excluding controllable non-melanoma basal cell or squamous cell carcinoma of the skin, carcinoma in situ of the breast or cervix, superficial bladder cancer, or other carcinoma in situ);
  • Known hepatic diseases of clinical significance, including active viral hepatitis, alcoholic hepatitis or other hepatitis, liver cirrhosis, fatty liver, hereditary liver disease;
  • Active tuberculosis (TB), receiving anti-tuberculosis therapy currently or within one year prior to screening;
  • Use of systemic immunosuppressive therapy for any active autoimmune disease within two years prior to Day 1 of the 1st cycle;
  • Vaccination of live-virus vaccine within 30 days after the start of planned treatment; Inactivated seasonal influenza vaccine was permitted;
  • Patients has HIV-positive;
  • Patients judged by the investigator to be inappropriate as a subject of this study.
  • History of severe allergic, quasi-allergic, or other hypersensitive reactions to chimeric or humanized antibodies or fusion proteins;
  • Known allergy to biological drugs produced from Chinese hamster ovary cells, or to citrate monohydrate, sodium citrate dihydrate, mannitol, polysorbate (components of the study drug);
  • Patients who have previously received allogeneic stem cells or parenchymal organ transplants.

Quoted from ClinicalTrials.gov, NCT06127303, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT06127303, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT06127303